Goyal Associates is a non-banking financial company that provides small-ticket loans to individuals and small businesses, primarily through its digital lending platform.
The company lacks a durable competitive advantage, as evidenced by negative net margins and extremely low returns on capital. There is no evidence of cost advantages or switching costs, and the business model appears easily replicable by larger, better-capitalized lenders.
Management has focused on small-scale lending and recently raised capital through a preferential issue of warrants. However, historical returns on equity and capital have been negligible or negative, suggesting that reinvested funds are not generating value for shareholders.
The business collapsed as the loss of its primary digital acquisition channel, the 'SalaryDay' app, proved fatal to its small-ticket lending model. Regulatory non-compliance, including chronic GST and listing fee defaults, eventually led to a total loss of the lending license or a permanent exchange suspension. Management's inability to generate positive returns on capital meant that the cash raised through warrants was slowly incinerated by negative margins and administrative incompetence, leaving shareholders with a hollow shell of a company that failed to meet even basic statutory obligations.
RichFakir rates Goyal Associates Ltd's business quality as poor — 8/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Goyal Associates Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Goyal Associates Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Goyal Associates Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →